Development of uterine adenomyosis after treatment with dopamine antagonists in mice

other OA: closed public-domain-us
View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-10

Dopamine antagonist treatment in mice increased prolactin, prolonged estrous cycles, and caused a high incidence of uterine adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Development of uterine adenomyosis was studied in SHN mice treated with psychotherapeutic drugs, sulpiride and perphenazine, and gastroenteric drug, metoclopramide, which act as dopamine antagonists to increase prolactin release from the pituitary gland. Administration of these drugs twice daily for 40-70 or 40-90 days of age induced an elevation in serum level of prolactin. Furthermore, the treated mice showed a prolongation of metestrous plus diestrous phase and a high incidence of uterine adenomyosis compared with vehicle-treated control mice. These results indicate that hyperprolactinemia produced by continuous treatment with psychotherapeutic and gastroenteric drugs is responsible for the occurrence of irregular estrous cycles and the genesis of uterine adenomyosis in mice.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Dopamine Antagonists Endometriosis Metoclopramide Perphenazine Sulpiride Uterine Neoplasms Animals Corpus Luteum Corpus Luteum Endometriosis Endometriosis Estrus Estrus Female Metoclopramide Metoclopramide Mice Perphenazine Perphenazine Prolactin

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
pubmed
last seen: 2026-05-13T22:12:05.481982+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine